The medical treatment of Cushing's syndrome.
Miller
J W
JW
Division of Endocrinology, Gerontology and Metabolism, Stanford University School of Medicine, California 94305.
Crapo
L
L
D000306:Adrenal Cortex Neoplasms / Q000188:drug therapy; D000311:Adrenal Glands / Q000601:surgery; D000616:Aminoglutethimide / Q000009:adverse effects / Q000627:therapeutic use; D000818:Animals; D001971:Bromocriptine / Q000009:adverse effects / Q000627:therapeutic use; D003480:Cushing Syndrome / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D003533:Cyproheptadine / Q000009:adverse effects / Q000627:therapeutic use; D004285:Dogs; D006736:Horses; D006801:Humans; D007654:Ketoconazole / Q000009:adverse effects / Q000627:therapeutic use; D008797:Metyrapone / Q000009:adverse effects / Q000627:therapeutic use; D015735:Mifepristone / Q000627:therapeutic use; D008939:Mitotane / Q000009:adverse effects / Q000627:therapeutic use; D015282:Octreotide / Q000627:therapeutic use; D010166:Palliative Care; D010902:Pituitary Gland / Q000000981:diagnostic imaging / Q000601:surgery; D011859:Radiography; D014635:Valproic Acid / Q000009:adverse effects / Q000627:therapeutic use
D000616:Aminoglutethimide; D003533:Cyproheptadine; D015735:Mifepristone; D001971:Bromocriptine; D014635:Valproic Acid; D008939:Mitotane; D007654:Ketoconazole; D015282:Octreotide; D008797:Metyrapone